Sarepta Therapeutics (NASDAQ:SRPT) and Harmony Biosciences (NASDAQ:HRMY) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Earnings and Valuation
This table compares Sarepta Therapeutics and Harmony Biosciences' top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
Sarepta Therapeutics | $380.83 million | 14.92 | $-715,080,000.00 | ($9.71) | -7.37 |
Harmony Biosciences | N/A | N/A | N/A | N/A | N/A |
Harmony Biosciences has lower revenue, but higher earnings than Sarepta Therapeutics.
Insider & Institutional Ownership
89.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 5.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Sarepta Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
Sarepta Therapeutics | -121.30% | -61.62% | -23.02% |
Harmony Biosciences | N/A | N/A | N/A |
Analyst Recommendations
This is a breakdown of recent ratings for Sarepta Therapeutics and Harmony Biosciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
Sarepta Therapeutics | 1 | 9 | 13 | 0 | 2.52 |
Harmony Biosciences | 0 | 0 | 3 | 0 | 3.00 |
Sarepta Therapeutics currently has a consensus target price of $150.4762, suggesting a potential upside of 110.40%. Harmony Biosciences has a consensus target price of $51.6667, suggesting a potential upside of 81.92%. Given Sarepta Therapeutics' higher probable upside, equities analysts clearly believe Sarepta Therapeutics is more favorable than Harmony Biosciences.
Summary
Sarepta Therapeutics beats Harmony Biosciences on 5 of the 9 factors compared between the two stocks.